Therapeutic efficacy of the live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in a preclinical model of bladder cancer

Intravesical instillation of bacillus Calmette-Gu érin (BCG) has been a first-line therapy for non–muscle-invasive bladder cancer for the last 4 decades. However, this treatment causes serious adverse events in a significant number of patients and a substantial percentage of recurrence episodes. MTBVAC is a live-attenuated vaccine derived from a Mycobacterium tuberculosis clinical isolate and is currently under evaluation in clinical trials to replace BCG as a tuberculosis vaccine. Here, we describe for the first time the potential of MTBVAC as a bladder cancer therapy in vitro and in vivo in a preclinical model.

Source: Translational Research - April 6, 2018 Category: Research Authors: Samuel Alvarez-Arguedas, Santiago Uranga, Manuel Mart ín, Javier Elizalde, Ana Belen Gomez, Esther Julián, Denise Nardelli-Haefliger, Carlos Martín, Nacho Aguilo Source Type: research